相关实验视频

Updated: Jun 1, 2025

TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients

TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients

Published on: April 13, 2021

在非糖尿病移植接受者中使用SGLT2i

Aina Quilis¹, Eva Gavela¹, Julia Kánter¹

¹Doctor Peset Aleixandre University Hospital, Valencia, Spain.

Transplantation proceedings

|January 18, 2025

概括

-葡萄糖共传输体-2 抑制剂 (SGLT2i) 在非糖尿病移植接受者 (KTRs) 中有效降低蛋白尿症. 这项研究发现,SGLT2i在这种人群中对蛋白尿的管理是安全和有益的.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
移植医学移植医学
药理学药理学是指药理学的学科.

背景情况:

-葡萄糖共传输体-2 抑制剂 (SGLT2i) 显示出降低蛋白尿的潜力,特别是在移植接受者 (KTRs) 中.
之前的研究已经强调了SGLT2i在糖尿病KTR患者中的好处.
这项研究调查了SGLT2i在非糖尿病KTRs中的疗效和安全性.

研究的目的:

评估SGLT2抑制剂在非糖尿病移植接受者的抗蛋白尿作用.
评估SGLT2抑制剂在这个特定患者群体中的安全性.
在引入SGLT2抑制剂后分析功能和其他临床参数的变化.

主要方法:

进行了一项单一中心的观察性研究.
包括非糖尿病移植接受者 (KTRs) 处方SGLT2抑制剂用于抗蛋白尿疗法.
临床和分析数据是在基线和治疗后6个月收集的.

主要成果:

在SGLT2抑制剂治疗6个月后,观察到蛋白尿的显著减少 (P = .025).
尿酸和高密度胆固醇水平的降低,以及eGFR的轻微降低.
在9.1%的患者中,SGLT2抑制剂因尿路感染或血液透析启动而被中止;没有发生心血管事件或死亡.

结论:

SGLT2 抑制剂在减少非糖尿病KTRs蛋白尿症方面表现出有效性.
在这个队列中,该疗法在6个月内表现出可接受的安全性.
在非糖尿病患者中,SGLT2抑制剂代表了蛋白尿症管理移植后的可行的治疗选择.

更多相关视频

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Published on: April 28, 2013

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Secondary Active Transport

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...